文献速递白血病造血干细胞移植与细胞治疗

TP53突变急性髓系白血病的单倍体相合造血干细胞移植

Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2022-11-08

本研究比较携带与不携带TP53突变的急性髓系白血病(AML)患者接受单倍体相合造血干细胞移植(haplo-HSCT)后的临床结局。TP53突变组与野生型组的2年累积复发率、非复发死亡率、无白血病生存率、总生存率、移植物抗宿主病及无GVHD无复发生存率均无显著差异;多因素分析显示TP53突变对上述结局无显著影响。作者认为TP53突变患者可能至少部分获益于haplo-HSCT。

要点

  • TP53突变组与野生型组2年累积复发率39.0% vs 21.2%(p=0.088),无显著差异。
  • 两组2年总生存率69.9% vs 81.3%(p=0.317),2年无白血病生存率57.7% vs 71.3%(p=0.205)。
  • 多因素分析显示TP53突变对复发、非复发死亡、生存及GVHD均无显著影响。

核心结论

  • TP53突变与野生型AML患者接受haplo-HSCT后2年临床结局无显著差异;作者认为TP53突变患者可能至少部分获益于haplo-HSCT,haplo-HSCT可能是此类患者的推荐治疗。

研究设计与样本

  • 研究比较接受单倍体相合造血干细胞移植(haplo-HSCT)的伴与不伴TP53突变的急性髓系白血病(AML)患者的临床结局。

主要发现

  • 2年累积复发率TP53突变组39.0% vs 野生型组21.2%(p=0.088)。
  • 2年非复发死亡率TP53突变组3.2% vs 野生型组8.4%(p=0.370)。
  • 2年无白血病生存率TP53突变组57.7% vs 野生型组71.3%(p=0.205)。
  • 2年总生存率TP53突变组69.9% vs 野生型组81.3%(p=0.317)。
  • 100天II-IV级急性GVHD累积发生率TP53突变组6.5% vs 野生型组20.7%(p=0.074)。

关键数值与推荐

  • 2年慢性GVHD累积发生率TP53突变组52.3% vs 野生型组53.1%(p=0.493)。
  • 2年无GVHD无复发生存率TP53突变组57.7% vs 野生型组69.6%(p=0.347)。
  • 多因素分析显示TP53突变对累积复发率、非复发死亡率、总生存率、GVHD、无白血病生存率及无GVHD无复发生存率均无显著影响。

临床怎么用

  • 作者认为伴TP53突变的AML患者可能至少部分获益于haplo-HSCT,haplo-HSCT可能是此类患者的推荐治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) patients with tumour protein p53 (TP53) mutations are often resistant to chemotherapy and have worse clinical outcomes than patients without TP53 mutations. In this study, we compared clinical outcomes of patients with AML with and without TP53 mutations who underwent haploidentical haematopoietic stem cell transplantation (haplo-HSCT). For the TP53-mutation group and TP53 wild-type group, the 2-year cumulative incidence of relapse (CIR) was (39.0% vs. 21.2% respectively, p = 0.088), the 2-year non-relapse mortality (NRM) rate was (3.2% vs. 8.4% respectively, p = 0.370), the 2-year leukaemia-free survival (LFS) was (57.7% vs. 71.3% respectively, p = 0.205), the 2-year overall survival (OS) rate was (69.9% vs. 81.3% respectively, p = 0.317), the 100-day cumulative incidence of Grade II-IV acute graft-versus-host disease (GvHD) was (6.5% vs. 20.7% respectively, p = 0.074), the 2-year cumulative incidence of chronic GvHD was (52.3% vs. 53.1% respectively, p = 0.493) and the 2-year GvHD-free/relapse-free survival (GRFS) was (57.7% vs. 69.6% respectively, p = 0.347). Our data showed that there were no significant differences in 2-year clinical outcomes between the two groups. Multivariable analysis showed TP53 mutations had no significant impact on CIR, NRM, OS, GvHD, LFS or GRFS. Our findings suggest that patients with AML with TP53 mutations may at least partially benefit from haplo-HSCT. Haplo-HSCT might be the recommended treatment for such patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huang T, Xu L, Zhang X, et al. Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia. Br J Haematol. 2022. PMID: 36345800. doi:10.1111/bjh.18538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。